These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 7165134)

  • 1. [The determination of heparin].
    Aiach M
    Ann Biol Clin (Paris); 1982; 40(6):645-50. PubMed ID: 7165134
    [No Abstract]   [Full Text] [Related]  

  • 2. The inhibition of the anticoagulant activity of heparin by platelets, brain phospholipids, and tissue factor.
    Ofosu FA; Cerskus AL; Hirsh J; Smith LM; Modi GJ; Blajchman MA
    Br J Haematol; 1984 Jun; 57(2):229-38. PubMed ID: 6733045
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monitoring of heparin treatment. Comparison of thrombin time, activated partial thromboplastin time, and plasma heparin concentration, and analysis of the behavior of antithrombin III.
    Bounameaux H; Marbet GA; Lämmle B; Eichlisberger R; Duckert F
    Am J Clin Pathol; 1980 Jul; 74(1):68-73. PubMed ID: 7395817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of two distinct heparin cofactors in human plasma. II. Inhibition of thrombin and activated factor X.
    Briginshaw GF; Shanberge JN
    Thromb Res; 1974 Mar; 4(3):463-77. PubMed ID: 4857333
    [No Abstract]   [Full Text] [Related]  

  • 5. [Laboratory controls of heparin therapy with thrombin time, partial thromboplastin time and activated recalcification time].
    Lutze G; Presser HJ; Urbahn H
    Z Gesamte Inn Med; 1989 Apr; 44(8):235-40. PubMed ID: 2662657
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validity of serine protease inhibition tests in the evaluation and monitoring of the effect of heparin and its fractions.
    Hoppensteadt DA; Walenga JM; Fareed J
    Semin Thromb Hemost; 1985 Apr; 11(2):112-20. PubMed ID: 3898369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Practical considerations on the measurement of low molecular weight heparin anti-Xa activity.
    Aiach M; Roncato M
    Semin Thromb Hemost; 1985 Apr; 11(2):108-11. PubMed ID: 4035362
    [No Abstract]   [Full Text] [Related]  

  • 8. Molecular weight of heparin versus biologic activity. Some additional considerations.
    Losito R; Losito C
    Semin Thromb Hemost; 1985 Jan; 11(1):29-33. PubMed ID: 2579437
    [No Abstract]   [Full Text] [Related]  

  • 9. Preliminary biochemical and pharmacologic studies on a chemically synthesized pentasaccharide.
    Walenga JM; Fareed J
    Semin Thromb Hemost; 1985 Apr; 11(2):89-99. PubMed ID: 4035370
    [No Abstract]   [Full Text] [Related]  

  • 10. Effects of heparin oligosaccharides with high affinity for antithrombin III in experimental venous thrombosis.
    Thomas DP; Merton RE; Barrowcliffe TW; Thunberg L; Lindahl U
    Thromb Haemost; 1982 Jun; 47(3):244-8. PubMed ID: 7112499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The monitoring of heparin administration by screening tests in experimental dogs.
    Mischke R; Jacobs C
    Res Vet Sci; 2001 Apr; 70(2):101-8. PubMed ID: 11356088
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Mechanisms of heparin resistance and their clinical significance].
    Barkagan ZS; Lychev VG; Bishevskiĭ KM; Tsyvkina LP; Glazunova GA
    Ter Arkh; 1982; 54(8):77-82. PubMed ID: 6753220
    [No Abstract]   [Full Text] [Related]  

  • 13. An algal sulfated galactan has an unusual dual effect on venous thrombosis due to activation of factor XII and inhibition of the coagulation proteases.
    Melo FR; Mourão PA
    Thromb Haemost; 2008 Mar; 99(3):531-8. PubMed ID: 18327401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma heparin values and hemostasis in equids after subcutaneous administration of low-dose calcium heparin.
    Gerhards H; Eberhardt C
    Am J Vet Res; 1988 Jan; 49(1):13-8. PubMed ID: 3354959
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of a low molecular weight heparin (Fragmin) and of unfractionated heparin on coagulation activation at the site of plug formation in vivo.
    Eichinger S; Wolz M; Nieszpaur-Los M; Schneider B; Lechner K; Eichler HG; Kyrle PA
    Thromb Haemost; 1994 Dec; 72(6):831-5. PubMed ID: 7740450
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anticoagulant property of a semi-synthesized sodium beta-1,4-glucan sulfate.
    Wang ZM; Li L; Li B; Guo SY
    Yao Xue Xue Bao; 2006 Apr; 41(4):323-7. PubMed ID: 16856476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preparation and anticoagulation activity of sodium cellulose sulfate.
    Wang ZM; Li L; Zheng BS; Normakhamatov N; Guo SY
    Int J Biol Macromol; 2007 Oct; 41(4):376-82. PubMed ID: 17602735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heparin, its fractions, fragments and derivatives. Some newer perspectives.
    Fareed J
    Semin Thromb Hemost; 1985 Jan; 11(1):1-9. PubMed ID: 3919446
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monitoring complex formation in the blood-coagulation cascade using aptamer-coated SAW sensors.
    Gronewold TM; Glass S; Quandt E; Famulok M
    Biosens Bioelectron; 2005 Apr; 20(10):2044-52. PubMed ID: 15741074
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Usefulness of fibrinopeptide A generation tests in experimental and clinical studies with low molecular weight heparin fractions.
    Emanuele RM; Fareed J; Walenga JM; Hoppensteadt DA; Baker WH
    Semin Thromb Hemost; 1985 Apr; 11(2):121-8. PubMed ID: 4035363
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.